Poniard Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Poniard Pharmaceuticals, Inc.
More C-Suite level pharma executives are lending their domain expertise to private equity firms, which then use their skills for commercial due diligence on targets or in an operating partner role in portfolio companies once a deal is sealed. PEs are also increasingly opting for control deals, at least in India, with an aim to run the acquired firm professionally thereon.
With $845m raised to date, ElevateBio will keep building its cell and gene therapy manufacturing capabilities and continue creating new companies and partnerships, but with a global focus.
A COVID-19 vaccine alliance between US, Japan, India and Australia announced funding for Johnson & Johnson’s vaccine made by Biological E. Will the arrangement be extended to other vaccines and will the alliance push US to address materials export concerns, recently raised by Serum Institute?
As vaccine makers tackle SARS-CoV-2 variants, WHO’s Chief Scientist feels it’s important to continue immunization programs with existing vaccines. Meanwhile, the rollouts mean the safety and efficacy landscape is set to change, said participants at a recent meet
- Other Names / Subsidiaries